Business
Zymeworks Announces Filing and Mailing of Materials for the Special Meeting to Approve Redomicile to Delaware
Redomicile anticipated to enhance long-term value for securityholders, provide opportunities for increased value of Zymeworks common shares, and better
About this update from Zymeworks Inc.
[{"type":"text","content":"\n\nRedomicile anticipated to enhance long-term value for securityholders, provide opportunities for increased value of Zymeworks common shares, and better position the Company for future growth\n\n\nZymeworks Board recommends that Zymeworks securityholders vote FOR the Redomicile resolution\n\n\nTo vote, contact Kingsdale Advisors at 1-855-476-7981 (within North America) or at 1-416-867-2272 (outside North America), or at [email protected]\n\n\n VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--\nZymeworks Inc. (“Zymeworks” or the “Company”) (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that the proxy statement (“Proxy Statement”) and related materials, dated September 2, 2022 for its special meeting of securityholders (the “Special Meeting”) have been filed publicly and are being mailed to securityholders. The Special Meeting will be held on Friday, October 7, 2022, at 9:00 a.m. Pacific time at the Pearl Room, Fairmont Pacific Rim, 1038 Canada Place, Vancouver, BC V6C 0B9 to approve the previously announced plan to become a Delaware corporation (the “Redomicile”). The record date for the meeting is August 24, 2022. Proxies submitted must be received by 9:00 a.m. Pacific time on Wednesday, October 5, 2022.\n\nAt the Special Meeting, Zymeworks securityholders will be asked to consider the Redomicile resolution to approve a series of transactions, including a corporate redomicile (collectively, the “Redomicile Transactions”). Pursuant to the Redomicile Transactions, holders of Zymeworks’ common shares will receive one share of common stock of Zymeworks Delaware Inc., a wholly-owned subsidiary of Zymeworks Inc., and which will become the parent corporation in connection with the completion of the Redomicile (“New Zymeworks”), or one exchangeable share in the capital of an indirect, wholly-owned subsidiary of New Zymeworks, as applicable, for each Zymeworks’ common share owned immediately prior to the Redomicile Transactions (with the aggregate number of exchangeable shares issued subject to a cap) as further outlined in the proxy statement.\n\nThe board of directors of Zymeworks (the “Zymeworks Board”) recommends that Zymeworks securityholders vote FOR the Redomicile resolution. The Company believes that the Redomicile will enhance long-term...